F32 F33
Conditions
Interventions
Group 1: Depressed group: Patients with major depressive disorder (MDD). This group will be immediately treated with 24 sessions of cognitive behavioral therapy. Blood samples, questionnaire data, and
Sponsors
Department of Clinical and Biological Psychology, Ulm University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: A diagnosis of major depressive disorder according to DSM-5; accepted psychological comorbidities: anxiety disorders, and somatoform disorders. Stable medication is permitted.
Exclusion criteria
Exclusion criteria: High suicidality, PTSD and complex PTSD, Borderline personality disorder, eating disorders, obsessive compulsive disorder, bipolar disorder, schizophrenia or a history of psychotic disorders, acute substance-related disorder, organic mental disorder, pregnancy and nursing, neurological diseases, immunological and endocrine disorders, autoimmune diseases such as chronic viral infections, rheumatoid arthritis, cardiovascular comorbidities, cancer, chronic obstructive pulmonary diseases, Body Mass Index (BMI) > 30, usage of certain intrauterine devices (eg. Mirena)
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will be measured using the whole blood and immune cells of the participants at the beginning of each time point. Oxygen-homeostasis-related parameters will be determined either from whole blood with a blood gas analyzer (glucose, lactate, pH, O2 and CO2 partial pressure), or from serum by clinical routine measurements (free iron, iron proteins, bilirubin), or with pulse oximeter (O2 saturation) and ear thermometer (body temperature). Inflammation parameters (CRP, IL-1beta, IL-2, IL-6, IL-10, TNF-alpha) will be determined from serum via enzyme-linked immunosorbent assay. Oxidative stress parameters will be determined from whole blood via Electron Spin Resonance (Reactive Oxygen Species) and indirectly from serum via enzyme-linked immunosorbent assay (8OH-dG, 8-isoprostane). | — |
Primary
| Measure | Time frame |
|---|---|
| Primary outcomes will be measured using the whole blood and immune cells of the participants at the beginning of each time point. ATP-turnover-related respiration, uncoupled respiration, and routine respiration will be measured from the immune cells, using high resolution respirometry. Mitochondrial density of the immune cells will be determined spectrophotometrically by measuring citrate syntase activity of the immune cells. Hemoglobin concentration and erythrocyte cell number per ml will be measured in whole blood. | — |
Countries
Germany
Contacts
Public ContactRezan Nehir Mavioglu
Department of Clinical and Biological Psychology, Ulm University
Outcome results
None listed